Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones

Tenaya Therapeutics, Inc.

Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.
Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.
Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.
Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Tenaya Therapeutics, Inc. entered into Collaboration Agreement with Alnylam Pharmaceuticals, Inc. valued at up to $10.0 million (effective 2026-03-04).

Action: entry
Agreement: collaboration
Counterparty: Alnylam Pharmaceuticals, Inc.
Value: up to $10.0 million
Effective: 2026-03-04

Exact text from the filing

On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”)

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.